Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeuMoDx Molecular Launches Coronavirus Test

Executive Summary

NeuMoDx Molecular announced plans to develop a coronavirus test for its own high-throughput molecular diagnostics platform.

You may also be interested in...



Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer

Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.

US CMS Providing Medicaid Coverage For COVID-19 Tests, But Congressman Still Sees Gaps For Testing Working Poor

The US Centers for Medicare and Medicaid Services (CMS) created a new billing code to help diagnose coronavirus in its beneficiaries on 5 March, as well as fact sheets on medical care and transport of COVID-19 patients, but patients who get their health care through low-cost insurance plans may not be able to afford the testing, said a House Committee chairman.

Thermo Fisher Scientific Announces $11.5Bn Buyout Of Qiagen

Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126379

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel